Day Net Income From Continuing Ops from 2010 to 2026

DAWN Stock  USD 11.16  0.62  5.26%   
Day One Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -90.2 M. During the period from 2010 to 2026, Day One Net Loss quarterly data regression pattern had range of 171.9 M and standard deviation of  52,525,342. View All Fundamentals
 
Net Loss  
First Reported
2020-03-31
Previous Quarter
-30.3 M
Current Value
-19.7 M
Quarterly Volatility
23.1 M
 
Covid
 
Interest Hikes
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 2.4 M or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 7.23, Dividend Yield of 0.0 or PTB Ratio of 2.23. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
  
Build AI portfolio with Day Stock
Check out the analysis of Day One Correlation against competitors.
Evaluating Day One's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Day One Biopharmaceuticals's fundamental strength.

Latest Day One's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Day One Biopharmaceuticals over the last few years. It is Day One's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Day Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(52,307,125)
Coefficient Of Variation(100.42)
Mean Deviation42,552,397
Median(16,984,000)
Standard Deviation52,525,342
Sample Variance2758.9T
Range171.9M
R-Value(0.74)
Mean Square Error1350.9T
R-Squared0.54
Significance0.0008
Slope(7,650,411)
Total Sum of Squares44142.6T

Day Net Income From Continuing Ops History

2026-90.2 M
2025-85.9 M
2024-95.5 M
2023-188.9 M
2022-142.2 M
2021-72.8 M
2020-43.8 M

About Day One Financial Statements

Day One investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-85.9 M-90.2 M

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving together with Day Stock

  0.78FHTX Foghorn TherapeuticsPairCorr

Moving against Day Stock

  0.75MYGN Myriad GeneticsPairCorr
  0.65HUMA HumacytePairCorr
  0.64EVAX Evaxion Biotech ASPairCorr
  0.39LTRN Lantern PharmaPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out the analysis of Day One Correlation against competitors.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.52)
Revenue Per Share
1.299
Quarterly Revenue Growth
(0.58)
Return On Assets
(0.19)
Return On Equity
(0.30)
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.